A detection kit for determining the content of creatine kinase isoenzymes in serum
By using monoclonal antibodies and crosslinking creatine kinase isoenzyme antibody-sensitized particles to bind nanoliposome particles, the problem of insufficient sensitivity and specificity detection of CK-MB in the prior art is solved, and high sensitivity is achieved and a high specific diagnosis of myocardial infarction.
Patent Information
- Application Number
- CN202111628445.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-12-28
AI Technical Summary
The existing methods for detecting creatine kinase isozyme CK-MB have low sensitivity, poor precision, and are easily disturbed by CK-BB giant CK and CK-Mt, resulting in diagnostic errors.
Monoclonal antibodies are used to directly bind CK-MB, and the sensitized particles of creatine kinase isoenzyme antibody are crosslinked and nanoliposome particles are combined to achieve high sensitivity and high specificity detection of CK-MB.
It improves the sensitivity and specificity of the detection, reduces interference to CK-BB giant CK and CK-Mt, and can more accurately detect micro-myocardial infarction, enhancing the reliability of the diagnosis.
Smart Images

Figure CN114460301B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to a detection kit for determining the content of creatine kinase isoenzymes in serum. Background Art
[0002] Creatine kinase isoenzymes, also known as serum creatine kinase isoenzymes, are an enzyme component. There are four isoenzyme forms: muscle type, brain type, hybrid type and mitochondrial type.
[0003] Muscle type (MM), brain type (BB), hybrid type (MB) and mitochondrial type (MiMi). The MM type is mainly present in various muscle cells, the BB type is mainly present in brain cells, the MB type is mainly present in cardiomyocytes, and the MiMi type is mainly present in cardiac and skeletal muscle mitochondria. The muscle type creatine kinase molecule is a dimer composed of two identical subunits. According to the primary structure of rabbit, human, chicken, and mouse creatine kinase that has been determined, the M-type subunit is composed of 387 amino acid residues, with a molecular weight of about 43kDa, and there are 8 sulfhydryl groups in the molecule, but no disulfide bonds. The giant panda muscle type creatine kinase is also a dimeric enzyme, each subunit is composed of 376 amino acid residues, and the molecular weight is 42KDa.
[0004] The isoenzymes of creatine kinase are of great significance in clinical diagnosis. When various diseases, including muscle atrophy and myocardial infarction, occur, the level of creatine kinase in human serum increases rapidly. It is believed that measuring the activity of creatine kinase in the diagnosis of myocardial infarction is more reliable than doing an electrocardiogram. In myocardial infarction, creatine kinase increases within 6 hours of onset, reaches a peak within 24 hours, and returns to normal within 3-4 days. Among them, the isoenzyme CK-MB of creatine kinase has the highest diagnostic specificity. Creatine kinase has attracted widespread attention and in-depth research due to its important physiological functions and clinical application value.
[0005] At present, the main method for detecting CK-MB, an isoenzyme of creatine kinase, is the immunosuppression method. However, in the clinical application process, the low-end sensitivity is relatively poor, the precision is poor, and it is interfered by CK-BB giant CK and CK-Mt, and sometimes the phenomenon of CKMB>CK occurs. The reagent of the present invention uses a monoclonal antibody to directly bind to CK-MB, which is not interfered by CK-BB giant CK and CK-Mt, and its diagnostic value for micro-myocardial infarction is better than traditional activity detection. Summary of the invention
[0006] The purpose of the present invention is to provide a detection kit for determining the content of creatine kinase isoenzyme in serum, which has the advantages of simple operation, high sensitivity, good specificity, rapid determination result and high determination result accuracy.
[0007] The objective of the present invention is achieved through the following technical solutions:
[0008] The present invention provides a detection kit for determining the content of creatine kinase isoenzymes in serum, comprising a reagent R1, a reagent R2 and a calibrator;
[0009] The reagent R1 is a phosphate buffer system;
[0010] The reagent R2 is a sensitized particle solution of cross-linked creatine kinase isozyme antibodies;
[0011] The calibrator comprises creatine kinase isoenzyme, buffer, protective agent and preservative.
[0012] The components and contents of the reagent R1 are as follows:
[0013]
[0014] The components and contents of the reagent R2 are as follows:
[0015]
[0016] The components and contents of the calibrator are as follows:
[0017]
[0018] The calibrators include 5 calibrators with creatine kinase isoenzyme concentrations of 0, 10, 30, 60, and 120 ng / mL, respectively.
[0019] In terms of volume ratio, the volume ratio of the reagents R1, R2 and the standard is 10-15:150-200:30-50.
[0020] Preferably, in terms of volume ratio, the volume ratio of the reagents R1, R1 and the standard is 10:150:50.
[0021] In reagent R2, the cross-linked creatine kinase isoenzyme antibody sensitized particles include: monoclonal antibody 1 sensitized particles formed by mouse anti-human creatine kinase isoenzyme antibody 1 cross-linked to the surface of nanoliposome particle one; and monoclonal antibody 2 sensitized particles formed by mouse anti-human creatine kinase isoenzyme antibody 2 cross-linked to the surface of nanoliposome particle two; the diameter of nanoliposome particle one is 60-86nm, and the diameter of nanoliposome particle two is 350-480nm.
[0022] in:
[0023] Mouse anti-human creatine kinase isoenzyme antibody 2: from Roche Diagnostics GmbH.
[0024] Mouse anti-human creatine kinase isoenzyme antibody 1: from Roche Diagnostics GmbH.
[0025] Compared with mouse anti-human creatine kinase isoenzyme antibody 2, mouse anti-human creatine kinase isoenzyme antibody 1 has a higher affinity with the antigen. Mouse anti-human creatine kinase isoenzyme antibody 1 coated with large-size microspheres can participate in the reaction first, and mouse anti-human creatine kinase isoenzyme antibody 2 coated with small-size microspheres can participate in the reaction later. The reaction order of large and small sensitizing particles can be controlled by controlling the order of antibody reactions, so that the reagent has both high sensitivity and high linearity.
[0026] The volume ratio of monoclonal antibody 1 sensitized particles to monoclonal antibody 2 sensitized particles in reagent R2 is 1:3-2:3.
[0027] The preparation method of the nanoliposome particle 1 comprises the following steps:
[0028] A. Dissolve lecithin and cholesterol in anhydrous ethanol and perform ultrasonic treatment to form a stable suspension membrane material, wherein the concentration of lecithin in the suspension membrane material is 30-50 mg / L;
[0029] B. Place PBS buffer in a container in a water bath, and add sodium sulfite solution and / or quaternary ammonium salt to form a mixed buffer;
[0030] C. Inject the suspension film material in step A into a mixed buffer, perform ultrasonic treatment and filter to obtain the nanoliposome particle 1.
[0031] The preparation method of the nanoliposome particle 2 comprises the following steps:
[0032] 1) Dissolve lecithin and cholesterol in anhydrous ethanol and perform ultrasonic treatment to form a stable suspension membrane material, wherein the concentration of lecithin in the suspension membrane material is 70-100 mg / L;
[0033] 2) Place the PBS buffer in a water bath and add sodium sulfite solution and / or quaternary ammonium salt to form a mixed buffer;
[0034] 3) Inject the suspension film material of step 1) into the mixed buffer, perform ultrasonic treatment and filter to obtain the nanoliposome particle 1.
[0035] The preparation method of the monoclonal antibody 1 sensitized particles comprises the following steps:
[0036] S1, centrifuging the nanoliposome particles, discarding the supernatant, resuspending them in a buffer, and ultrasonically dispersing them to obtain a resuspension;
[0037] S2. Add NHS solution to the re-suspension and mix well, then add EDC solution and mix well, stir, and then centrifuge, discard the supernatant, dissolve and suspend the precipitate after centrifugation with buffer, sonicate, add mouse anti-human creatine kinase isoenzyme antibody 1, stir and centrifuge; suspend the precipitate after centrifugation in blocking solution, sonicate, and obtain the monoclonal antibody 1 sensitized particles.
[0038] The preparation method of the monoclonal antibody 2 sensitized particles comprises the following steps:
[0039] S1, centrifuging the nanoliposome particles, discarding the supernatant, resuspending them in a buffer, and ultrasonically dispersing them to obtain a resuspension;
[0040] S2. Add NHS solution to the re-suspension and mix well, then add EDC solution and mix well, stir, and then centrifuge, discard the supernatant, dissolve and suspend the precipitate after centrifugation with buffer, sonicate, add mouse anti-human creatine kinase isoenzyme antibody 2, stir and centrifuge; suspend the precipitate after centrifugation in blocking solution, sonicate, and obtain the monoclonal antibody 2 sensitized particles.
[0041] The content ratio of monoclonal antibody 1 sensitized particles to monoclonal antibody 2 sensitized particles in reagent R2 is 1:3-2:3.
[0042] In reagent R1, the polymer is selected from polyethylene glycol 6000, polyethylene glycol 8000, dextran 10000-40000Kd, or one or more thereof.
[0043] Two mouse anti-human creatine kinase isozyme antibodies were cross-linked to the surface of two nanoliposome particles of different sizes under different chemical cross-linking conditions.
[0044] The optimal cross-linking condition for mouse anti-human creatine kinase isoenzyme antibody 1 is glycine buffer (0.1 mol / L, pH 5.2), and the optimal cross-linking condition for mouse anti-human creatine kinase isoenzyme antibody 2 is MES buffer (0.1 mol / L, pH 6.1). The ratio of antibody addition to liposome particles is 12-20 mg / 10 mL.
[0045] When preparing liposomes with a diameter of 60-86 nm, the concentration of sodium sulfite is 2.5 mol / L, the added volume is 5-8 ml, the concentration of quaternary ammonium salt is 0.05 mol / L, and the added volume is 1-3 ml; when preparing liposomes with a diameter of 350-480 nm, the concentration of sodium sulfite is 2.5 mol / L, the added volume is 3-6 ml, the concentration of quaternary ammonium salt is 0.05 mol / L, and the added volume is 2-4 ml.
[0046] The preservative is selected from one or more of sodium azide, sodium benzoate, potassium sorbate, thimerosal, Proclin-300 or phenol, and the concentration range is 10-500 mM.
[0047] The concentration of sodium sulfite and quaternary ammonium salt determines the surface charge of liposome particles. When preparing liposomes with a diameter of 60-86nm, the concentration of sodium sulfite is 2.5mol / L, the added volume is 5-8ml, and the concentration of quaternary ammonium salt is 0.05mol / L, and the added volume is 1-3ml; when preparing liposomes with a diameter of 350-480nm, the concentration of sodium sulfite is 2.5mol / L, the added volume is 3-6ml, and the concentration of quaternary ammonium salt is 0.05mol / L, and the added volume is 2-4ml.
[0048] The invention adds cholesterol, and the preparation of microspheres is more controllable, and the long-term storage of the microspheres is more stable. Sodium sulfite is added to increase the surface charge of the microspheres, and the stability of the reagent is better. The number of charges on the surface of the liposomes is controlled by controlling the concentration of sodium sulfite and quaternary ammonium salt of the large and small microspheres, so that the order in which the large and small microspheres participate in the reaction can be controlled. The large microspheres participate in the reaction first because they have less charge, and the small microspheres participate in the reaction later because they have more charge. The large microspheres participate in the reaction first to improve the sensitivity of the reagent, and the small microspheres participate in the reaction later to improve the linear range of the reagent.
[0049] The components of the allergenic particle sealing solution are as follows: MOPSO 0.2mol / L pH7.8, sodium chloride 0.8mol / L, trehalose 5%, bovine serum albumin 1-2%, preservative 0.1%. The content of allergenic particles is 0.1-0.5g / L
[0050] The preservative is selected from one or more of sodium azide, sodium benzoate, potassium sorbate, thimerosal, Proclin-300 or phenol, and the concentration range is 10-500mM.
[0051] Compared with the prior art, the present invention has the following beneficial effects:
[0052] (1) By adding cholesterol, the problem of insufficient toughness of liposome microspheres and easy to precipitate is solved, thereby improving the success rate of liposome microsphere preparation and achieving the beneficial effect of improving the stability of reagent reaction;
[0053] (2) By controlling the concentration of added sodium sulfite, the problem of insufficient surface charge of liposomes and easy accumulation is solved, achieving the beneficial effect of improving the stability of the reagent;
[0054] (3) The technical feature of controlling the surface charge of liposomes by controlling the concentration of sodium sulfite and quaternary ammonium salt solves the reaction sequence of antibodies and achieves the beneficial effect of improving the sensitivity and linear range of the reagent at the same time;
[0055] (4) By screening a pair of monoclonal antibodies with different reaction affinities and coating the small and large microspheres respectively, the reaction order of the large and small microspheres can be controlled, thereby achieving the beneficial effect of improving the sensitivity and linear range of the reagent at the same time;
[0056] (5) The present invention directly detects the CKMB content in the sample through the CKMB antigen-antibody reaction. Compared with the existing conventional immunosuppression reagents, it solves the problems of poor detection precision and high false positive rate of low-end reagents in the prior art.
[0057] (6) Mouse anti-human creatine kinase isoenzyme antibody 1 has a higher affinity with the antigen than mouse anti-human creatine kinase isoenzyme antibody 2. Mouse anti-human creatine kinase isoenzyme antibody 1 coated with large-diameter microspheres can participate in the reaction first, and mouse anti-human creatine kinase isoenzyme antibody 2 coated with small-diameter microspheres can participate in the reaction later. The reaction order of large and small sensitized particles can be controlled by controlling the order of antibody reaction, so that the reagent has high sensitivity and high linearity at the same time. The kit of the present invention is easy to operate, has high sensitivity and good specificity, can quickly measure the results, and the measurement results are highly accurate. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0059] Figure 1 To verify the correlation test results of the detection reagents in Example 1;
[0060] Figure 2 To verify the linear graph of Example 4 in Example 3;
[0061] Figure 3 It is the linear graph of Comparative Example 1 in Verification Example 3;
[0062] Figure 4 It is the linear graph of Comparative Example 2 in Verification Example 3. DETAILED DESCRIPTION
[0063] The present invention is described in detail below in conjunction with embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, some adjustments and improvements can also be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.
[0064] Example 1
[0065] This embodiment provides a method for preparing nanoliposome particles, comprising the following steps:
[0066] Weigh 3g of lecithin and 0.1g of cholesterol, dissolve in 10ml of anhydrous ethanol, and form a stable light yellow uniform suspension after water bath ultrasonic treatment for 5min, and put it into an acid burette. Use a measuring cylinder to take 40ml of PBS buffer (pH6.8) in a 100mL beaker and place it in a 40℃ water bath, then add 8ml of 2.5mol / L sodium sulfite solution, and then add 2mL of 0.05mol / L quaternary ammonium salt, and inject the membrane material of the burette into the PBS buffer at a constant temperature of 40℃ at a rate of 1 drop per second while stirring, and the injection process lasts for about 20min. The prepared liposome suspension is placed in an eggplant-shaped bottle for water bath ultrasonic treatment, and the ultrasonic treatment is paused for 5s every 5s. After a total of 30min of ultrasonic time, a white translucent liposome suspension is obtained, and after removing large particle impurities with a microporous filter membrane, it is stored at 2-8℃.
[0067] The diameter of the liposome particles prepared in this example is 60-86 nm.
[0068] Example 2
[0069] This embodiment provides a method for preparing nanoliposome particles II, comprising the following steps:
[0070] Weigh 6g of lecithin and 0.1g of cholesterol, dissolve in 10ml of anhydrous ethanol, and form a stable light yellow uniform suspension after water bath ultrasonic treatment for 5min, and put it into an acid burette. Use a measuring cylinder to take 40ml of PBS buffer (pH6.8) in a 100mL beaker and place it in a 40℃ water bath, then add 6ml of 2.5mol / L sodium sulfite solution, and then add 4mL of 0.05mol / L quaternary ammonium salt, and inject the membrane material of the burette into the PBS buffer at a constant temperature of 40℃ at a rate of 1 drop per second while stirring, and the injection process lasts for about 20min. The prepared liposome suspension is placed in an eggplant-shaped bottle for water bath ultrasonic treatment, and the ultrasonic treatment is paused for 5s every 5s. After a total of 30min of ultrasonic time, a white translucent liposome suspension is obtained, and after removing large particle impurities with a microporous filter membrane, it is stored at 2-8℃.
[0071] The diameter of the liposome particles prepared in this example is 350-480 nm.
[0072] Example 3
[0073] 1. The preparation method of monoclonal antibody 2 sensitized particles is as follows:
[0074] S1. Centrifuge the nanoliposome particles prepared in Example 2, remove the supernatant, resuspend them in MES buffer (0.1 mol / L, pH 6.1), and disperse them by ultrasonication to obtain a resuspension;
[0075] S2, adding NHS solution to the resuspension and mixing, then adding EDC solution and mixing, stirring at room temperature, and then centrifuging;
[0076] S3, dissolving and suspending the precipitate after centrifugation in step S2 with MES buffer (0.1 mol / L, pH 6.1), sonicating, and then adding mouse anti-human creatine kinase isoenzyme antibody 2 purchased from Roche, stirring at room temperature and centrifuging;
[0077] S4, dissolving and suspending the precipitate after centrifugation in step S3 with MES buffer (0.1 mol / L, pH 6.1), sonicating, and then centrifuging;
[0078] S5, dissolving and suspending the precipitate after centrifugation in step S4 with MES buffer (0.1 mol / L, pH 6.1), sonicating, and then centrifuging;
[0079] S6. The precipitate obtained after centrifugation in step S5 is suspended in a blocking solution and subjected to ultrasound to obtain the monoclonal antibody 2 sensitized particles.
[0080] In step S3, the ratio of the added amount of the mouse monoclonal antibody 2 to the liposome particles is 12 mg / 10 ml; the components of the sensitized particle blocking solution are as follows: MOPSO 0.2 mol / L pH7.8, sodium chloride 0.8 mol / L, trehalose 5%, bovine serum albumin 1-2%, and preservative 0.1%.
[0081] 2. The preparation method of monoclonal antibody 1 sensitized particles is as follows:
[0082] S1. Centrifuge the nanoliposome particles prepared in Example 1, remove the supernatant, resuspend them in glycine buffer (0.1 mol / L, pH 5.2), and disperse them by ultrasonication to obtain a resuspension;
[0083] S2, adding NHS solution to the resuspension and mixing, then adding EDC solution and mixing, stirring at room temperature, and then centrifuging;
[0084] S3, dissolving and suspending the precipitate after centrifugation in step S2 with glycine buffer (0.1 mol / L, pH 5.2), sonicating, then adding mouse anti-human creatine kinase isoenzyme antibody 1 purchased from Roche, stirring at room temperature and centrifuging;
[0085] S4, dissolving and suspending the precipitate after centrifugation in step S3 with glycine buffer (0.1 mol / L, pH 5.2), sonicating, and then centrifuging;
[0086] S5, dissolving and suspending the precipitate after centrifugation in step S4 with glycine buffer (0.1 mol / L, pH 5.2), sonicating, and then centrifuging;
[0087] S6. The precipitate obtained after centrifugation in step S5 is suspended in a blocking solution and subjected to ultrasound to obtain the monoclonal antibody 1 sensitized particles.
[0088] Preferably, in step S3, the ratio of the added amount of the mouse anti-human creatine kinase isozyme antibody 1 to the liposome particles is 12 mg / 10 ml.
[0089] The components of the sensitized particle sealing solution are as follows: MOPSO 0.2 mol / L pH 7.8, sodium chloride 0.8 mol / L, trehalose 5%, bovine serum albumin 1-2%, and preservative 0.1%.
[0090] 3. Sensitized particles of cross-linked creatine kinase isoenzyme antibodies
[0091] The monoclonal antibody 1 sensitized particles and the monoclonal antibody 2 sensitized particles were mixed at a volume ratio of 1:2 to prepare cross-linked creatine kinase isoenzyme antibody sensitized particles.
[0092] Example 4
[0093] The formula and content of the kit of this embodiment are as follows:
[0094] R1: Preparation table
[0095]
[0096] R2: Preparation table
[0097]
[0098] Calibrators: Preparation Table
[0099]
[0100]
[0101] Here, the percentages are by volume.
[0102] In reagent R2, the sensitized particles of cross-linked creatine kinase isozyme antibodies are prepared in Example 3.
[0103] In the kit, the volume ratio of the reagents R1, R1 and the standard is 10:150:50.
[0104] Comparative Example 1
[0105] The difference between the kit provided in this comparative example and Example 4 is that the sensitized particles of the cross-linked creatine kinase isozyme antibody in the R2 reagent only include the monoclonal antibody 1 sensitized particles prepared in Example 3.
[0106] Comparative Example 2
[0107] The difference between the kit provided in this comparative example and Example 4 is that the sensitized particles of cross-linked creatine kinase isozyme antibodies in the R2 reagent only include the monoclonal antibody 2 sensitized particles prepared in Example 3.
[0108] Comparative Example 3
[0109] The CKMB detection kit (immunosuppression method) of our company was used as a comparative kit for performance comparison with the examples of the present application.
[0110] Comparative Example 4
[0111] The CKMB detection kit (chemiluminescence method) provided by Roche Diagnostics GmbH was selected as a comparative kit for performance comparison with the examples of the present application.
[0112] Comparative Example 5
[0113] The kit provided in this comparative example is different from that in Example 4 in that the monoclonal antibody 1 sensitizing particles and the monoclonal antibody 2 sensitizing particles are replaced by monoclonal antibody 1 latex microsphere sensitizing particles and monoclonal antibody 2 latex microsphere sensitizing particles, that is, both the nanoliposome particles 1 and the nanoliposome particles 2 are latex microspheres.
[0114] The preparation method of the monoclonal antibody 1 latex microsphere sensitized particles of this comparative example is as follows:
[0115] ①, centrifuge the latex microspheres purchased from Bangslab, USA, remove the supernatant, resuspend them in glycine buffer (0.1 mol / L, pH 5.2), and disperse them by ultrasonic to obtain a resuspension;
[0116] ②. Add NHS solution to the resuspension and mix well, then add EDC solution and mix well, stir at room temperature, and then centrifuge;
[0117] ③, dissolve and suspend the precipitate after centrifugation in step ② with glycine buffer (0.1 mol / L, pH 5.2), sonicate, then add mouse anti-human creatine kinase isoenzyme antibody 1, stir at room temperature and centrifuge;
[0118] ④. Dissolve and suspend the precipitate obtained after centrifugation in step ③ with glycine buffer (0.1 mol / L, pH 5.2), sonicate, and then centrifuge;
[0119] ⑤. Dissolve and suspend the precipitate obtained after centrifugation in step ④ with glycine buffer (0.1 mol / L, pH 5.2), sonicate, and then centrifuge;
[0120] ⑥. The precipitate obtained after centrifugation in step ⑤ is suspended in a blocking solution and subjected to ultrasound to obtain the monoclonal antibody 1 latex microsphere sensitized particles.
[0121] The preparation method of the monoclonal antibody 2 latex microsphere sensitized particles of this comparative example is as follows:
[0122] ①, centrifuge the latex microspheres purchased from Bangslab, USA, remove the supernatant, resuspend them in MES buffer (0.1 mol / L, pH 6.1), and disperse them by ultrasonic to obtain a resuspension;
[0123] S2, adding NHS solution to the resuspension and mixing, then adding EDC solution and mixing, stirring at room temperature, and then centrifuging;
[0124] S3, dissolving and suspending the precipitate after centrifugation in step s2 with MES buffer (0.1 mol / L, pH 6.1), sonicating, then adding mouse anti-human creatine kinase isoenzyme antibody 2, stirring at room temperature and centrifuging;
[0125] S4, dissolving and suspending the precipitate after centrifugation in step s3 with MES buffer (0.1 mol / L, pH 6.1), sonicating, and then centrifuging;
[0126] S5, dissolving and suspending the precipitate after centrifugation in step s4 with MES buffer (0.1 mol / L, pH 6.1), sonicating, and then centrifuging;
[0127] S6, suspending the precipitate after centrifugation in step s5 in a blocking solution, and ultrasonicating to obtain the monoclonal antibody 2 latex microsphere sensitized particles.
[0128] The remaining methods and parameters are the same as in Example 4.
[0129] Comparative Example 6
[0130] The difference between the kit provided in this comparative example and Example 4 is that cholesterol is not added when preparing the liposome particles.
[0131] Effect verification
[0132] Verification Example 1: Comparison of the correlation of test kits
[0133] Using the reagent of the present invention (Example 4) and a CKMB kit of a well-known domestic company (Comparative Example 4), 50 human sera (including normal and abnormal samples) were tested according to their respective parameters, and correlation analysis was performed on the measured values.
[0134] Depend on Figure 1 The results show that the correlation between the two kits is R 2 =0.999, and the regression equation is y=0.998x+0.01. The results show that the reagent has a good correlation with the imported reagent in measuring human serum, and has good specificity and accuracy. The accuracy of the result reaches 98.7%.
[0135] Verification Example 2: Comparison of kit detection sensitivity
[0136] The purpose of this experiment is to test the minimum detection sensitivity of the test kit when testing clinical samples.
[0137] The kit of Example 4, the kit of Comparative Example 1, the kit of Comparative Example 2, a standard substance, a blank solution (generally physiological saline and purified water), and a normal human serum sample were used.
[0138] Machine: Hitachi 7170 automatic biochemical analyzer.
[0139] Operation steps: Use physiological saline or deionized water to dissolve the sample, then dilute it by 50% into 5 points, test each sample 5 times together with the zero point, calculate the average value, and obtain the SD value.
[0140] Result interpretation: As shown in Table 3, based on the test data, the SD value and CV value were calculated, and 1SD and 2SD were calculated respectively. Starting from the smallest value, the value of the average value - 2SD above the zero point average value + 2SD is the minimum detection sensitivity of the kit.
[0141] Table 1. Sensitivity test (unit: ng / mL)
[0142]
[0143]
[0144] The experimental results show that the sensitivity of the CKMB kit (Example 4) provided by the present invention can reach 0.25 ng / mL, while that provided by Comparative Example 1 can only reach 2 ng / mL, and that provided by Comparative Example 2 can reach 0.25 ng / mL, indicating that the sensitivity of the kit of the present invention and Comparative Example 2 is greatly improved.
[0145] Verification Example 3: Kit Linearity Comparison
[0146] The purpose of this experiment is to detect the linear range that can be measured by the kit provided by the present invention.
[0147] Take a high-value sample with a concentration of about 120 ng / mL and use 0.9% NaCl as a diluent. Dilute it into 4 points at a ratio of 1 / 5, 2 / 5, 3 / 5, and 4 / 5, plus a blank sample and a high-value sample, a total of 6 samples are measured 3 times each using the methods of Experimental Example 1 and Experimental Example 2 according to the standard experimental operation steps, and the measured mean (yi) is calculated respectively. The linear regression equation and correlation coefficient (r) are obtained using the diluted concentration (xi) of the 7 samples as the independent variable and the measured mean (yi) as the dependent variable. Calculate the correlation coefficient (r) and the number of samples (n) according to formula (1).
[0148]
[0149] Substitute the dilution concentration xi in the above method into the linear regression equation to calculate the estimated value of yi and the relative deviation or absolute deviation between yi and the estimated value of yi, which should comply with relevant regulations.
[0150] Experimental results:
[0151] Table 2. Linear range of Example 4 (unit: ng / mL)
[0152]
[0153]
[0154] Table 3. Linear range of comparative example 1
[0155]
[0156] Table 4. Linear range of comparative example 2 (unit: ng / mL)
[0157]
[0158]
[0159] in Figure 2 To verify the linear graph of Example 4 in Example 3; Figure 3 It is the linear graph of Comparative Example 1 in Verification Example 3; Figure 4 It is the linear graph of Comparative Example 2 in Verification Example 3.
[0160] From the experimental results, it can be seen that comparative example 1 has poor sensitivity but good linearity, comparative example 2 has good sensitivity but poor linearity, and embodiment 4 has good sensitivity and linearity.
[0161] Verification Example 4:
[0162] Performance comparison of Example 4 and Comparative Example 3 (immunosuppression CKMB detection kit)
[0163] 1. Specificity
[0164] The specific experimental effects of the CKMB detection kit (Example 4) provided by the present invention and the comparative example 4 were verified.
[0165] Collect 50 CKMB negative samples and test them with the CKMB kit provided in Example 4, Comparative Example 3 and Comparative Example 4, and compare the results of positive rate
[0166] Table 5. Specificity evaluation
[0167]
[0168]
[0169]
[0170] The experimental results show that the kit provided by the present invention (Example 4) has 0 false positive cases in the detection of normal samples, while the probability of false positives in the detection of the immunosuppression kit (Comparative Example 3) reaches 6%, indicating that the CKMB reagent provided by the present invention has excellent performance in terms of specificity.
[0171] 2. Precision
[0172] The CKMB reagent provided by the present invention was used to detect low-value samples and high-value samples 10 times, and the Mean, SD, and CV were calculated. The precision of the reagent was evaluated, and the results are shown in Tables 6 and 7.
[0173] Table 6. Precision of Example 4
[0174]
[0175]
[0176] Table 7. Comparative Example 3 Precision
[0177]
[0178] The test results show that the CKMB kit provided in Example 4 is superior to the CKMB kit of immunosuppression method on the market in terms of precision.
[0179] Verification Example 5:
[0180] Liposome microspheres are more sensitive than latex microspheres.
[0181] The test method is the same as the steps described in Verification Example 2. The experimental results are as follows:
[0182] Table 8. Sensitivity results, unit (ng / mL)
[0183]
[0184]
[0185] The experimental results show that the sensitivity of the CKMB kit (Example 4) provided by the present invention can reach 0.25 ng / mL, while that provided by Comparative Example 5 can only reach 2 ng / mL, indicating that the sensitivity of the kit of the present invention and Comparative Example 5 is greatly improved.
[0186] Verification Experiment Example 7: Stability
[0187] The purpose of this experiment is to detect the stability of the kit provided by the present invention at 37°C.
[0188] The test kits provided in Example 4 and Comparative Example 6 were placed in an oven at 37° C. for 3 days, and were taken out for quality control measurement after 3 days.
[0189] Machine: Hitachi 7170 automatic biochemical analyzer.
[0190] Experimental results:
[0191] Table 9. L quality control results at 37℃
[0192]
[0193] Table 10 H quality control results at 37℃
[0194]
[0195] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.
Claims
1. A detection kit for determining the content of creatine kinase isoenzymes in serum, characterized in that: Includes reagent R1, reagent R2 and calibrators; The reagent R1 is a phosphate buffer system; The reagent R2 is a sensitized particle solution of cross-linked creatine kinase isozyme antibodies; The calibrator comprises creatine kinase isoenzyme, buffer, protective agent and preservative; The components and contents of the reagent R1 are as follows: The components and contents of the reagent R2 are as follows: In reagent R2, the cross-linked creatine kinase isoenzyme antibody sensitized particles include: mouse anti-human creatine kinase isoenzyme antibody 1 cross-linked to the surface of nanoliposome particle 1 to form monoclonal antibody 1 sensitized particles; and mouse anti-human creatine kinase isoenzyme antibody 2 cross-linked to the surface of nanoliposome particle 2 to form monoclonal antibody 2 sensitized particles; the diameter of nanoliposome particle 1 is 60-86nm, and the diameter of nanoliposome particle 2 is 350-480nm; The preparation method of the nanoliposome particle 1 comprises the following steps: A. Dissolve lecithin and cholesterol in anhydrous ethanol and perform ultrasonic treatment to form a stable suspension membrane material, wherein the concentration of lecithin in the suspension membrane material is 30-50 mg / L; B. Place PBS buffer in a container in a water bath, add sodium sulfite solution and quaternary ammonium salt to form a mixed buffer; C. injecting the suspension film material of step A into a mixed buffer, ultrasonically treating and filtering, to obtain the nanoliposome particle 1; The preparation method of the nanoliposome particle 2 comprises the following steps: 1) Dissolve lecithin and cholesterol in anhydrous ethanol and perform ultrasonic treatment to form a stable suspension membrane material, wherein the concentration of lecithin in the suspension membrane material is 70-100 mg / L; 2) Place the PBS buffer in a water bath and add sodium sulfite solution and quaternary ammonium salt to form a mixed buffer; 3) Inject the suspension film material of step 1) into the mixed buffer, perform ultrasonic treatment and filter to obtain the nanoliposome particle II.
2. The kit according to claim 1, characterized in that The components and contents of the calibration products are as follows:
3. The kit according to claim 1, characterized in that The content ratio of monoclonal antibody 1 sensitizing particles to monoclonal antibody 2 sensitizing particles in the reagent R2 is 1:3-2:
3.
4. The kit according to claim 1, characterized in that The preparation method of the monoclonal antibody 1 sensitized particles comprises the following steps: S1, centrifuging the nanoliposome particles, discarding the supernatant, resuspending them in a buffer, and ultrasonically dispersing them to obtain a resuspension; S2. Add NHS solution to the re-suspension and mix well, then add EDC solution and mix well, stir, and then centrifuge, discard the supernatant, dissolve and suspend the precipitate after centrifugation with buffer, sonicate, add mouse anti-human creatine kinase isoenzyme antibody 1, stir and centrifuge; suspend the precipitate after centrifugation in blocking solution, sonicate, and obtain the monoclonal antibody 1 sensitized particles.
5. The kit according to claim 1, characterized in that The preparation method of the monoclonal antibody 2 sensitized particles comprises the following steps: S1, centrifuging the nanoliposome particles, discarding the supernatant, resuspending them in a buffer, and ultrasonically dispersing them to obtain a resuspension; S2. Add NHS solution to the re-suspension and mix well, then add EDC solution and mix well, stir, and then centrifuge, discard the supernatant, dissolve and suspend the precipitate after centrifugation with buffer, sonicate, add mouse anti-human creatine kinase isoenzyme antibody 2, stir and centrifuge; suspend the precipitate after centrifugation in blocking solution, sonicate, and obtain the monoclonal antibody 2 sensitized particles.
Citation Information
Patent Citations
Application of isoliquiritigenin lipidosome in preparation of medicines for treating adriamycin-induced acute (chronic) myocardial toxicity
CN107898774A
Chemiluminescent quantitative detection kit for detection of creatine kinase MB in serum / plasma and preparation method thereof
CN109490549A
Spherical protein particles and methods for making and using them
US20040219224A1
Treatment of Immunological Disease Using Berberine Nanoparticles
US20200276172A1
